Literature DB >> 21926054

Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries.

D Dewailly1, H Gronier, E Poncelet, G Robin, M Leroy, P Pigny, A Duhamel, S Catteau-Jonard.   

Abstract

BACKGROUND: Polycystic ovarian morphology (PCOM) at ultrasound is currently used in the diagnosis of polycystic ovary syndrome (PCOS). We hypothesized that the previously proposed threshold value of 12 as an excessive number of follicles per ovary (FN) is no longer appropriate because of current technological developments. In this study, we have revisited the thresholds for FN and for the serum Anti-Müllerian hormone (AMH) level (a possible surrogate for FN) for the definition of PCOM.
METHODS: Clinical, hormonal and ultrasound data were consecutively recorded in 240 patients referred to our department between 2008 and 2010 for exploration of hyperandrogenism (HA), menstrual disorders and/or infertility.
RESULTS: According to only their symptoms, patients were grouped as: non-PCOS without HA and with ovulatory cycles (group 1, n = 105), presumption of PCOS with only HA or only oligo-anovulation (group 2, n = 73) and PCOS with HA and oligo-anovulation (group 3, n = 62). By cluster analysis using androgens, LH, FSH, AMH, FN and ovarian volume, group 1 appeared to be constituted of two homogeneous clusters, most likely a non-PCOM non-PCOS subgroup (n = 66) and a PCOM, non-PCOS (i.e. asymptomatic) subgroup (n = 39). Receiver operating characteristic curve analysis was applied to distinguish the non-PCOM non-PCO members of group 1 and to group 3. For FN and serum AMH respectively, the areas under the curve were 0.949 and 0.973 and the best compromise between sensitivity (81 and 92%) and specificity (92 and 97%) was obtained with a threshold values of 19 follicles and 35 pmol/l (5 ng/ml).
CONCLUSIONS: For the definition of PCOM, the former threshold of >12 for FN is no longer valid. A serum AMH >35 pmol/l (or >5 ng/ml) appears to be more sensitive and specific than a FN >19 and should be therefore included in the current diagnostic classifications for PCOS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21926054     DOI: 10.1093/humrep/der297

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  90 in total

Review 1.  Polycystic ovary syndrome throughout a woman's life.

Authors:  José Bellver; Luis Rodríguez-Tabernero; Ana Robles; Elkin Muñoz; Francisca Martínez; José Landeras; Juan García-Velasco; Juan Fontes; Mónica Álvarez; Claudio Álvarez; Belén Acevedo
Journal:  J Assist Reprod Genet       Date:  2017-09-27       Impact factor: 3.412

Review 2.  The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum.

Authors:  Robert L Rosenfield
Journal:  J Pediatr Adolesc Gynecol       Date:  2014-08-27       Impact factor: 1.814

3.  New perspectives on the role of anti-Müllerian hormone (AMH) in women.

Authors:  Renato Pasquali
Journal:  Ann Transl Med       Date:  2018-12

4.  Anti-Mullerian hormone normogram in an Irish subfertile population.

Authors:  M N Naasan; C Harrity; L Pentony; E Mocanu
Journal:  Ir J Med Sci       Date:  2014-02-23       Impact factor: 1.568

5.  Impact of CD4+ lymphocytes and HIV infection on Anti-Müllerian Hormone levels in a large cohort of HIV-infected and HIV-uninfected women.

Authors:  Rebecca Scherzer; Peter Bacchetti; Geralyn Messerlian; Johanna Goderre; Pauline M Maki; David B Seifer; Kathryn Anastos; Roksana Karim; Ruth M Greenblatt
Journal:  Am J Reprod Immunol       Date:  2014-10-23       Impact factor: 3.886

6.  Antimüllerian hormone levels are lower in BRCA2 mutation carriers.

Authors:  Lauren Johnson; Mary D Sammel; Susan Domchek; Allison Schanne; Maureen Prewitt; Clarisa Gracia
Journal:  Fertil Steril       Date:  2017-05       Impact factor: 7.329

7.  Nesfatin-1 and other hormone alterations in polycystic ovary syndrome.

Authors:  Rulin Deniz; Bilgin Gurates; Suleyman Aydin; Husnu Celik; Ibrahim Sahin; Yakup Baykus; Zekiye Catak; Aziz Aksoy; Cihan Citil; Sami Gungor
Journal:  Endocrine       Date:  2012-02-25       Impact factor: 3.633

8.  BRCA1 germline mutations may be associated with reduced ovarian reserve.

Authors:  Erica T Wang; Margareta D Pisarska; Catherine Bresee; Yii-Der Ida Chen; Jenny Lester; Yalda Afshar; Carolyn Alexander; Beth Y Karlan
Journal:  Fertil Steril       Date:  2014-09-23       Impact factor: 7.329

9.  Polycystic ovary morphology: age-based ultrasound criteria.

Authors:  Hyun-Jun Kim; Judith M Adams; Jens A Gudmundsson; Gudmundur Arason; Cindy T Pau; Corrine K Welt
Journal:  Fertil Steril       Date:  2017-08-12       Impact factor: 7.329

10.  Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Self-reporting Features of Polycystic Ovary Syndrome.

Authors:  Nina M Clark; Amanda J Podolski; Eric D Brooks; Donna R Chizen; Roger A Pierson; Denis C Lehotay; Marla E Lujan
Journal:  Reprod Sci       Date:  2014-02-11       Impact factor: 3.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.